S170 Incidence of Acute Pancreatitis With GLP-1 Receptor Agonists Use Across Obesity and Type 2 Diabetes Phenotypes: A Multi-Center Analysis

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), approved for obesity and type 2 diabetes mellitus (T2DM) treatment, have been linked to acute pancreatitis (AP). We evaluated whether AP risk with GLP-1 RA therapy differs among patients with obesity alone, T2DM alone, or both. Methods: A retrospective cohort study was performed using TriNetX data base to compare 730-day AP risk in adults (≥18 y) newly prescribed GLP-1 RAs with obesity only, T2DM only, or both. The primary aim was to determine if combined obesity and T2DM modified AP risk vs either condition alone. We excluded patients with prior AP (ICD-10 K85.x) or missing demographics. Two pairwise, one-to-one propensity score–matched comparisons—(1) obesity + GLP-1 RA vs obesity + T2DM + GLP-1 RA and (2) T2DM + GLP-1 RA vs obesity + T2DM + GLP-1 RA—balanced 34 baseline covariates (demographics; BMI; HbA1c; gallstone disease; alcohol use disorder; hypertriglyceridemia; chronic kidney disease; hypertension; hyperlipidemia; pancreatitis-associated medications), yielding matched cohorts of 35,099 and 66,880 patients, respectively. Incident AP risk was expressed as adjusted odds ratios (aORs) with 95% confidence intervals (CIs) via conditional logistic regression and time-to-event risk as adjusted hazard ratios (aHRs) with 95% CIs via Cox models with Kaplan–Meier/log-rank analyses. Results: In the obesity comparison, AP incidence was 0.3% in each cohort; the aOR was 0.76 (95% CI, 0.58–1.00) and the aHR 0.87 (95% CI, 0.67–1.12), with 730-day pancreatitis-free survival of 99.64% vs 99.58% (log-rank P = 0.28). In the T2DM comparison, incidence was 0.5% vs 0.4%; the aOR was 1.14 (95% CI, 0.97–1.35) and the aHR 1.13 (95% CI, 0.96–1.34), with survival of 99.50% vs 99.56% (P = 0.14). No comparison reached statistical significance. Conclusion: Our study limitations include retrospective design, possibility of misclassification bias and confounding by other causes of AP. Despite this, our study did not show any significant difference in incidence of AP across metabolic phenotypes. The data appears to suggest that the causal mechanisms for AP may be independent of the phenotypes. Future studies perhaps with longer follow up are required to corroborate our findings and clarify if GLP1 RA dose and duration, pre-existent cholelithiasis and other factors can predict risk of AP.